Abbott India Limited (ABBOTINDIA) - Total Assets
Based on the latest financial reports, Abbott India Limited (ABBOTINDIA) holds total assets worth Rs56.94 Billion INR (≈ $615.83 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Abbott India Limited's book value for net asset value and shareholders' equity analysis.
Abbott India Limited - Total Assets Trend (2005–2025)
This chart illustrates how Abbott India Limited's total assets have evolved over time, based on quarterly financial data.
Abbott India Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Abbott India Limited's total assets of Rs56.94 Billion consist of 80.5% current assets and 19.5% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs4.80 Billion | 9.5% |
| Accounts Receivable | Rs7.10 Billion | 12.0% |
| Inventory | Rs8.82 Billion | 14.9% |
| Property, Plant & Equipment | Rs3.48 Billion | 5.9% |
| Intangible Assets | Rs64.60 Million | 0.1% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Abbott India Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ABBOTINDIA stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Abbott India Limited's current assets represent 80.5% of total assets in 2025, an increase from 22.3% in 2005.
- Cash Position: Cash and equivalents constituted 9.5% of total assets in 2025, up from 4.0% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is inventory at 14.9% of total assets.
Abbott India Limited Competitors by Total Assets
Key competitors of Abbott India Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Abbott India Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.75 | 2.25 | 3.18 |
| Quick Ratio | 2.09 | 1.71 | 2.48 |
| Cash Ratio | 0.90 | 0.80 | 0.00 |
| Working Capital | Rs24.82 Billion | Rs17.24 Billion | Rs21.53 Billion |
Abbott India Limited - Advanced Valuation Insights
This section examines the relationship between Abbott India Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.02 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | 13.9% |
| Total Assets | Rs59.17 Billion |
| Market Capitalization | $5.85 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Abbott India Limited's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Abbott India Limited's assets grew by 13.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Abbott India Limited (2005–2025)
The table below shows the annual total assets of Abbott India Limited from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs59.17 Billion ≈ $639.93 Million |
+13.94% |
| 2024-03-31 | Rs51.93 Billion ≈ $561.66 Million |
+14.00% |
| 2023-03-31 | Rs45.56 Billion ≈ $492.66 Million |
+7.85% |
| 2022-03-31 | Rs42.24 Billion ≈ $456.82 Million |
+9.99% |
| 2021-03-31 | Rs38.40 Billion ≈ $415.33 Million |
+8.28% |
| 2020-03-31 | Rs35.47 Billion ≈ $383.58 Million |
+20.60% |
| 2019-03-31 | Rs29.41 Billion ≈ $318.05 Million |
+21.72% |
| 2018-03-31 | Rs24.16 Billion ≈ $261.30 Million |
+16.96% |
| 2017-03-31 | Rs20.66 Billion ≈ $223.41 Million |
+27.79% |
| 2016-03-31 | Rs16.17 Billion ≈ $174.82 Million |
+17.68% |
| 2015-03-31 | Rs13.74 Billion ≈ $148.55 Million |
+20.58% |
| 2014-03-31 | Rs11.39 Billion ≈ $123.20 Million |
+25.58% |
| 2013-03-31 | Rs9.07 Billion ≈ $98.10 Million |
+13.35% |
| 2012-03-31 | Rs8.00 Billion ≈ $86.54 Million |
+74.98% |
| 2011-03-31 | Rs4.57 Billion ≈ $49.46 Million |
+17.85% |
| 2010-03-31 | Rs3.88 Billion ≈ $41.97 Million |
+10.71% |
| 2009-03-31 | Rs3.51 Billion ≈ $37.91 Million |
+6.11% |
| 2008-03-31 | Rs3.30 Billion ≈ $35.73 Million |
-2.97% |
| 2007-03-31 | Rs3.40 Billion ≈ $36.82 Million |
+9.71% |
| 2006-03-31 | Rs3.10 Billion ≈ $33.57 Million |
-0.56% |
| 2005-03-31 | Rs3.12 Billion ≈ $33.75 Million |
-- |
About Abbott India Limited
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, … Read more